<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557163</url>
  </required_header>
  <id_info>
    <org_study_id>TS-142-205-01</org_study_id>
    <nct_id>NCT04557163</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)</brief_title>
  <official_title>Drug-drug Interaction Study With TS-142 in Healthy Adult Subjects (Concomitant Administration of Itraconazole)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center, single-sequence study to evaluate the concomitant&#xD;
      effects of the potent CYP3A inhibitor itraconazole on the single-dose pharmakokinetics,&#xD;
      safety and tolerability of oral TS-142 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Actual">November 14, 2020</completion_date>
  <primary_completion_date type="Actual">November 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Maximum observed concentration of unchanged form of TS-142 and its metabolite in plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-last)</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration of TS-142 and its metabolite in plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC(0-infinity)</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinite time of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tmax</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Time to Cmax of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>T1/2</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Terminal phase half-life of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vz/F</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Apparent Volume of Distribution During Terminal Phase of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>CL/F</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Apparent Oral Clearance of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Î»z</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>terminal elimination rate constant of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC(0-24h)</measure>
    <time_frame>Sampling at pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 48 hours post-dose of TS-142 on Day 1 or Day 6, in addition, at 96, 144, 192, 240 hours post-dose of TS-142 on Day 6.</time_frame>
    <description>Area under the concentration-time curve from time zero to time 24 h of TS-142 and its metabolite in plasma.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Subjects receiving TS-142 and itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 5 mg TS-142 on Day 1. Subjects will also receive twice-a-day of 200 mg itraconazole on Day 3 and an once-daily single dose of 200 mg itraconazole from Day 4 to Day 7 and single dose of 1 mg TS-142 on Day 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142</intervention_name>
    <description>TS-142 will be given as 1 mg per capsule administered orally with water.</description>
    <arm_group_label>Subjects receiving TS-142 and itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole will given as 50 mg per capsule administered orally with water.</description>
    <arm_group_label>Subjects receiving TS-142 and itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese male age 20 to 39 years at the signing of informed consent&#xD;
&#xD;
          -  Subjects whose body mass index (BMI) within the range 18.5 - 25.0 kg/m2, exclusive of&#xD;
             25.0&#xD;
&#xD;
          -  Subjects who judged by the principal investigator(s) or subinvestigator(s) to be&#xD;
             appropriate as a subjects of this study based on the results of screening tests and&#xD;
             the tests obtained prior to the administration of the investigational drug. (Those who&#xD;
             have no abnormal findings in the physical examination, vital signs, and standard&#xD;
             12-lead ECG in the screening test and the test obtained prior to administration of the&#xD;
             investigational drug, and whose clinical test results are within the standard values&#xD;
             of the clinical trial site. However, if who showed abnormal findings but not&#xD;
             clinically significant, they can be enrolled in clinical trials based on comprehensive&#xD;
             consideration of medical viewpoints by the principal investigator(s) or&#xD;
             subinvestigator(s).)&#xD;
&#xD;
          -  Subjects who understand, and have willingness and ability to read and sign, the&#xD;
             informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have any disease and are judged not to be healthy based on the medical&#xD;
             viewpoints by the principal investigator(s) or subinvestigator(s)&#xD;
&#xD;
          -  Subjects who have an inappropriate history for participation in this study, including&#xD;
             hepatic, renal, cardiovascular, hematological, endocrinological, metabolic,&#xD;
             respiratory, gastrointestinal, dermatological, neurological, urological,&#xD;
             immunological, psychiatric abnormalities or diseases&#xD;
&#xD;
          -  Subjects who have any history of drug or food allergies&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

